
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1616513/publications.pdf Version: 2024-02-01



DONNA H RVAN

#	Article	IF	CITATIONS
1	2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults. Journal of the American College of Cardiology, 2014, 63, 2985-3023.	1.2	2,477
2	Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes. New England Journal of Medicine, 2013, 369, 145-154.	13.9	2,294
3	2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults. Circulation, 2014, 129, S102-38.	1.6	2,114
4	Comparison of Weight-Loss Diets with Different Compositions of Fat, Protein, and Carbohydrates. New England Journal of Medicine, 2009, 360, 859-873.	13.9	1,680
5	Reduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes: One-year results of the Look AHEAD trial. Diabetes Care, 2007, 30, 1374-1383.	4.3	1,369
6	Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 342-362.	1.8	891
7	Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet, The, 2011, 377, 1341-1352.	6.3	765
8	Management of obesity. Lancet, The, 2016, 387, 1947-1956.	6.3	715
9	Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Contemporary Clinical Trials, 2003, 24, 610-628.	2.0	698
10	Fast-food consumption among US adults and children: Dietary and nutrient intake profile. Journal of the American Dietetic Association, 2003, 103, 1332-1338.	1.3	560
11	Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. American Journal of Clinical Nutrition, 2012, 95, 297-308.	2.2	547
12	The Science of Obesity Management: An Endocrine Society Scientific Statement. Endocrine Reviews, 2018, 39, 79-132.	8.9	522
13	Contributions of total body fat, abdominal subcutaneous adipose tissue compartments, and visceral adipose tissue to the metabolic complications of obesity. Metabolism: Clinical and Experimental, 2001, 50, 425-435.	1.5	496
14	Joint international consensus statement for ending stigma of obesity. Nature Medicine, 2020, 26, 485-497.	15.2	468
15	Oneâ€year Weight Losses in the Look AHEAD Study: Factors Associated With Success. Obesity, 2009, 17, 713-722.	1.5	439
16	The Relationship of Waist Circumference and BMI to Visceral, Subcutaneous, and Total Body Fat: Sex and Race Differences. Obesity, 2011, 19, 402-408.	1.5	421
17	NIH working group report: Innovative research to improve maintenance of weight loss. Obesity, 2015, 23, 7-15.	1.5	405
18	Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over. Current Obesity Reports, 2017, 6, 187-194.	3.5	371

#	Article	IF	CITATIONS
19	Fourâ€Year Weight Losses in the Look AHEAD Study: Factors Associated With Longâ€Term Success. Obesity, 2011, 19, 1987-1998.	1.5	356
20	Sibutramine Produces Doseâ€Related Weight Loss. Obesity, 1999, 7, 189-198.	4.0	333
21	Sleep Deprivation by the "Flower Pot―Technique and Spatial Reference Memory. Physiology and Behavior, 1997, 61, 249-256.	1.0	222
22	Prevalence of Risk Factors for Metabolic Syndrome in Adolescents. JAMA Pediatrics, 2009, 163, 371.	3.6	222
23	Executive summary: Guidelines (2013) for the management of overweight and obesity in adults. Obesity, 2014, 22, S5-39.	1.5	219
24	ls 5% weight loss a satisfactory criterion to define clinically significant weight loss?. Obesity, 2015, 23, 2319-2320.	1.5	208
25	Racial differences in abdominal depot–specific adiposity in white and African American adults. American Journal of Clinical Nutrition, 2010, 91, 7-15.	2.2	194
26	Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a <i>Diabetes Care</i> Editors' Expert Forum. Diabetes Care, 2015, 38, 1567-1582.	4.3	180
27	A Doubleâ€Blind Randomized Placebo ontrolled Trial of Sibutramine. Obesity, 1996, 4, 263-270.	4.0	173
28	Two‥ear Internetâ€Based Randomized Controlled Trial for Weight Loss in Africanâ€American Girls. Obesity, 2006, 14, 1231-1243.	1.5	171
29	Assessment and Lifestyle Management of Patients With Obesity. JAMA - Journal of the American Medical Association, 2014, 312, 943.	3.8	171
30	Prevention of Type 2 Diabetes in Subjects With Prediabetes and Metabolic Syndrome Treated With Phentermine and Topiramate Extended Release. Diabetes Care, 2014, 37, 912-921.	4.3	169
31	COVID 19 and the Patient with Obesity $\hat{a} \in$ The Editors Speak Out. Obesity, 2020, 28, 847-847.	1.5	162
32	The Association of Body Weight, Dietary Intake, and Energy Expenditure with Dietary Restraint and Disinhibition. Obesity, 1995, 3, 153-161.	4.0	152
33	Association of Body Mass with Dietary Restraint and Disinhibition. Appetite, 1995, 25, 31-41.	1.8	149
34	Impact of an Intensive Lifestyle Intervention on Use and Cost of Medical Services Among Overweight and Obese Adults With Type 2 Diabetes: The Action for Health in Diabetes. Diabetes Care, 2014, 37, 2548-2556.	4.3	144
35	Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design. American Heart Journal, 2020, 229, 61-69.	1.2	137
36	Mediators of Weight Loss in a Familyâ€Based Intervention Presented over the Internet. Obesity, 2004, 12, 1050-1059.	4.0	129

#	Article	IF	CITATIONS
37	Nonsurgical Weight Loss for Extreme Obesity in Primary Care Settings. Archives of Internal Medicine, 2010, 170, 146.	4.3	127
38	The Accumulating Data to Optimally Predict Obesity Treatment (ADOPT) Core Measures Project: Rationale and Approach. Obesity, 2018, 26, S6-S15.	1.5	124
39	The energy balance model of obesity: beyond calories in, calories out. American Journal of Clinical Nutrition, 2022, 115, 1243-1254.	2.2	123
40	Effect of repeated stress on body weight and body composition of rats fed low- and high-fat diets. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 1998, 275, R1928-R1938.	0.9	117
41	Guideline Recommendations for Obesity Management. Medical Clinics of North America, 2018, 102, 49-63.	1.1	117
42	Weight-Loss Therapy in Type 2 Diabetes: Effects of Phentermine and Topiramate Extended Release. Diabetes Care, 2014, 37, 3309-3316.	4.3	115
43	Drug Treatment of the Overweight Patient. Gastroenterology, 2007, 132, 2239-2252.	0.6	107
44	Medical Therapy for the Patient With Obesity. Circulation, 2012, 125, 1695-1703.	1.6	98
45	Effects of Tyrosine, Phentermine, Caffeined-amphetamine, and Placebo on Cognitive and Motor Performance Deficits During Sleep Deprivation. Nutritional Neuroscience, 2003, 6, 237-246.	1.5	94
46	Ethnicâ€ <b>6</b> pecific BMI and Waist Circumference Thresholds. Obesity, 2011, 19, 1272-1278.	1.5	92
47	Clinical Practice Guidelines for Healthy Eating for the Prevention and Treatment of Metabolic and Endocrine Diseases in Adults: Cosponsored by the American Association of Clinical Endocrinologists/The American College of Endocrinology and the Obesity Society. Endocrine Practice, 2013, 19, 1-82.	1.1	90
48	Weight Loss Maintenance Following a Primary Care Intervention for Lowâ€income Minority Women. Obesity, 2008, 16, 2462-2467.	1.5	87
49	Sibutramine: A Novel New Agent for Obesity Treatment. Obesity, 1995, 3, 553S-559S.	4.0	86
50	A Primary Care Weight Management Intervention for Lowâ€Income Africanâ€American Women. Obesity, 2006, 14, 1412-1420.	1.5	82
51	Preface to the full report. Obesity, 2014, 22, S1-3.	1.5	78
52	Update on obesity pharmacotherapy. Annals of the New York Academy of Sciences, 2014, 1311, 1-13.	1.8	74
53	<scp>GLP</scp> â€1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond. Obesity, 2015, 23, 1119-1129.	1.5	74
54	Increased glucocorticoid response to a novel stress in rats that have been restrained. Physiology and Behavior, 2004, 81, 557-568.	1.0	73

#	Article	IF	CITATIONS
55	Body Mass Index and the Risk of All-Cause Mortality Among Patients With Type 2 Diabetes Mellitus. Circulation, 2014, 130, 2143-2151.	1.6	72
56	Weight-loss diets and 2-y changes in circulating amino acids in 2 randomized intervention trials. American Journal of Clinical Nutrition, 2016, 103, 505-511.	2.2	69
57	A pilot church-based weight loss program for African-American adults using church members as health educators: a comparison of individual and group intervention. Ethnicity and Disease, 2005, 15, 373-8.	1.0	68
58	Wise Mind Project: A School-based Environmental Approach for Preventing Weight Gain in Children*. Obesity, 2007, 15, 906-917.	1.5	65
59	Effect of an Environmental Schoolâ€Based Obesity Prevention Program on Changes in Body Fat and Body Weight: A Randomized Trial. Obesity, 2012, 20, 1653-1661.	1.5	65
60	Four-Year Change in Cardiorespiratory Fitness and Influence on Glycemic Control in Adults With Type 2 Diabetes in a Randomized Trial. Diabetes Care, 2013, 36, 1297-1303.	4.3	59
61	Pharmaceutical Cost Savings of Treating Obesity with Weight Loss Medications. Obesity, 1999, 7, 523-531.	4.0	58
62	Validity of a Telephone-Administered 24-Hour Dietary Recall in Telephone and Non-Telephone Households in the Rural Lower Mississippi Delta Region. Journal of the American Dietetic Association, 2001, 101, 216-222.	1.3	56
63	Corticotropin-releasing factor receptor antagonist infused into the locus coeruleus attenuates immobilization stress-induced defensive withdrawal in rats. Neuroscience Letters, 1996, 220, 167-170.	1.0	53
64	New Obesity Guidelines. JAMA - Journal of the American Medical Association, 2014, 311, 23.	3.8	53
65	Evidenceâ€based weight loss interventions: Individualized treatment options to maximize patient outcomes. Diabetes, Obesity and Metabolism, 2021, 23, 50-62.	2.2	53
66	The Effects of Paradoxical Sleep Deprivation and Valine on Spatial Learning and Brain 5-HT Metabolism. Physiology and Behavior, 1999, 67, 643-649.	1.0	52
67	Distribution of glucokinase, glucose transporter GLUT2, sulfonylurea receptor-1, glucagon-like peptide-1 receptor and neuropeptide Y messenger RNAs in rat brain by quantitative real time RT-PCR. Molecular Brain Research, 2003, 113, 139-142.	2.5	52
68	Challenging obesity: Patient, provider, and expert perspectives on the roles of available and emerging nonsurgical therapies. Obesity, 2015, 23, S1-S26.	1.5	52
69	Effect of capsinoids on energy metabolism in human subjects. British Journal of Nutrition, 2010, 103, 38-42.	1.2	51
70	Is it Time to Change the Way We Report and Discuss Weight Loss?. Obesity, 2009, 17, 619-621.	1.5	50
71	Early behavioral adherence predicts short and long-term weight loss in the POUNDS LOST study. Journal of Behavioral Medicine, 2010, 33, 305-314.	1.1	50
72	Time for a new obesity narrative. Lancet, The, 2018, 392, 1384-1386.	6.3	50

#	Article	IF	CITATIONS
73	Adherence is a multi-dimensional construct in the POUNDS LOST trial. Journal of Behavioral Medicine, 2010, 33, 35-46.	1.1	49
74	Racial Differences in the Association Between Gestational Diabetes Mellitus and Risk of Type 2 Diabetes. Journal of Women's Health, 2012, 21, 628-633.	1.5	49
75	Effect of Diet Composition and Weight Loss on Resting Energy Expenditure in the POUNDS LOST Study. Obesity, 2012, 20, 2384-2389.	1.5	48
76	Increasing Incidence of Gestational Diabetes Mellitus in Louisiana, 1997–2009. Journal of Women's Health, 2012, 21, 319-325.	1.5	47
77	Aggressive Blood Pressure Control Increases Coronary Heart Disease Risk Among Diabetic Patients. Diabetes Care, 2013, 36, 3287-3296.	4.3	47
78	Intensive Weight Loss Intervention and Cancer Risk in Adults with Type 2 Diabetes: Analysis of the Look AHEAD Randomized Clinical Trial. Obesity, 2020, 28, 1678-1686.	1.5	47
79	CRF Receptor Antagonist Attenuates Immobilization Stress-Induced Norepinephrine Release in the Prefrontal Cortex in Rats. Brain Research Bulletin, 1997, 42, 431-434.	1.4	45
80	High Prevalence of Food Insecurity and Hunger in Households in the Rural Lower Mississippi Delta Journal of Rural Health, 2004, 20, 173-181.	1.6	43
81	Trunk Versus Extremity Adiposity and Cardiometabolic Risk Factors in White and African American Adults. Diabetes Care, 2011, 34, 1415-1418.	4.3	43
82	Apolipoprotein-E deficiency results in an altered stress responsiveness in addition to an impaired spatial memory in young mice. Brain Research, 1998, 788, 151-159.	1.1	42
83	Fiber Intake Predicts Weight Loss and Dietary Adherence in Adults Consuming Calorie-Restricted Diets: The POUNDS Lost (Preventing Overweight Using Novel Dietary Strategies) Study. Journal of Nutrition, 2019, 149, 1742-1748.	1.3	42
84	A Paradigm of Experimentally Induced Mild Hyperthyroidism: Effects on Nitrogen Balance, Body Composition, and Energy Expenditure in Healthy Young Men <sup>1</sup> . Journal of Clinical Endocrinology and Metabolism, 1997, 82, 765-770.	1.8	40
85	Americans on Diet. Journal of the American Dietetic Association, 2002, 102, 1247-1251.	1.3	39
86	HbA1c and Lower-Extremity Amputation Risk in Low-Income Patients With Diabetes. Diabetes Care, 2013, 36, 3591-3598.	4.3	39
87	Overexpression of agouti protein and stress responsiveness in mice. Physiology and Behavior, 2001, 73, 599-608.	1.0	37
88	Louisiana (LA) Health: Design and methods for a childhood obesity prevention program in rural schools. Contemporary Clinical Trials, 2008, 29, 783-795.	0.8	37
89	Ethnic Differences in Selfâ€reported and Measured Obesit. Obesity, 2009, 17, 571-577.	1.5	37
90	Blood Pressure and Stroke Risk Among Diabetic Patients. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 3653-3662.	1.8	37

#	Article	IF	CITATIONS
91	Identification of urocortin mRNA antisense transcripts in rat tissue. Brain Research Bulletin, 2000, 53, 317-324.	1.4	36
92	Predicting successful long-term weight loss from short-term weight-loss outcomes: new insights from a dynamic energy balance model (the POUNDS Lost study). American Journal of Clinical Nutrition, 2015, 101, 449-454.	2.2	35
93	Pharmacologic Treatment Options for Obesity: What Is Old Is New Again. Current Hypertension Reports, 2013, 15, 182-189.	1.5	34
94	Changes in Food Intake and Body Weight Associated with Basic Combat Training. Military Medicine, 2002, 167, 248-253.	0.4	33
95	Dietary Fat Intake Modifies the Effect of a Common Variant in the LIPC Gene on Changes in Serum Lipid Concentrations during a Long-Term Weight-Loss Intervention Trial. Journal of Nutrition, 2015, 145, 1289-1294.	1.3	33
96	Clinical Evaluation of the Overweight Patient. Endocrine, 2000, 13, 167-186.	2.2	31
97	Three New Perspectives on the Perfect Storm: What's Behind the Obesity Epidemic?. Obesity, 2018, 26, 9-10.	1.5	31
98	Increasing prevalence of diabetes in middle or low income residents in Louisiana from 2000 to 2009. Diabetes Research and Clinical Practice, 2011, 94, 262-268.	1.1	30
99	Rats fed only during the light period are resistant to stress-induced weight loss. Physiology and Behavior, 2002, 76, 543-550.	1.0	29
100	Partial Meal Replacement Plan and Quality of the Diet at 1 Year: Action for Health in Diabetes (Look) Tj ETQqO O	0 rgBT /0 0.4	verlock 10 Tf
101	Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice?. Journal of Obesity and Metabolic Syndrome, 2021, 30, 196-208.	1.5	27
102	Racial Disparities in Diabetic Complications in an Underinsured Population. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 4446-4453.	1.8	26
103	Pretreatment Fasting Glucose and Insulin as Determinants of Weight Loss on Diets Varying in Macronutrients and Dietary Fibers—The POUNDS LOST Study. Nutrients, 2019, 11, 586.	1.7	26
104	Perceptions of Community Nutrition and Health Needs in the Lower Mississippi Delta: A Key Informant Approach. Journal of Nutrition Education and Behavior, 2001, 33, 266-277.	0.5	25
105	The "Rolling Store:" an economical and environmental approach to the prevention of weight gain in African American women. Ethnicity and Disease, 2009, 19, 7-12.	1.0	25
106	Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss. Obesity, 2022, 30, 841-857.	1.5	25
107	Incremental Weight Loss Improves Cardiometabolic Risk in Extremely Obese Adults. American Journal of Medicine, 2011, 124, 931-938.	0.6	24
108	Treatment of the Obese Patient in Primary Care: Targeting and Meeting Goals and Expectations. Postgraduate Medicine, 2013, 125, 67-77.	0.9	24

#	Article	IF	CITATIONS
109	Guidelines for Obesity Management. Endocrinology and Metabolism Clinics of North America, 2016, 45, 501-510.	1.2	24
110	Body Mass Index and the Risk of Dementia among Louisiana Low Income Diabetic Patients. PLoS ONE, 2012, 7, e44537.	1.1	24
111	Comparison of Body Composition Methods in Obese Africanâ€American Women. Obesity, 2006, 14, 415-422.	1.5	23
112	The State of Obesity and Obesity Research. JAMA - Journal of the American Medical Association, 2010, 304, 1835.	3.8	23
113	Effects of Intensive Lifestyle Intervention on All-Cause Mortality in Older Adults With Type 2 Diabetes and Overweight/Obesity: Results From the Look AHEAD Study. Diabetes Care, 2022, 45, 1252-1259.	4.3	23
114	Stigma and obesity: the crux of the matter. Lancet Public Health, The, 2019, 4, e549-e550.	4.7	22
115	A Comparison of Tyrosine against Placebo, Phentermine, Caffeine, andd-Amphetamine During Sleep Deprivation. Nutritional Neuroscience, 2003, 6, 221-235.	1.5	21
116	Dietary fish oil does not protect rats exposed to restraint or sleep deprivation stress. Physiology and Behavior, 2003, 78, 759-765.	1.0	20
117	Expression Levels of Genes Likely Involved in Glucose-sensing in the Obese Zucker Rat Brain. Nutritional Neuroscience, 2004, 7, 67-74.	1.5	20
118	H.E.A.L.T.H.: Efficacy of an Internet/Population-Based Behavioral Weight Management Program for the U.S. Army. Journal of Diabetes Science and Technology, 2011, 5, 178-187.	1.3	20
119	Body Image Changes Associated With Participation in an Intensive Lifestyle Weight Loss Intervention. Obesity, 2011, 19, 1290-1295.	1.5	17
120	MEDICATING THE OBESE PATIENT. Endocrinology and Metabolism Clinics of North America, 1996, 25, 989-1004.	1.2	16
121	Perception of Sweetness Intensity Determines Women's Hedonic and other Perceptual Responsiveness to Chocolate Food. Appetite, 1998, 31, 37-48.	1.8	16
122	Short-Term Food Restriction and Refeeding Alter Expression of Genes Likely Involved in Brain Glucosensing. Experimental Biology and Medicine, 2003, 228, 943-950.	1.1	16
123	Increased obesity in children living in rural communities of Louisiana. Pediatric Obesity, 2009, 4, 160-165.	3.2	16
124	Increasing prevalence of hypertension in low income residents within Louisiana State University Health Care Services Division Hospital System. European Journal of Internal Medicine, 2012, 23, e179-e184.	1.0	16
125	Why Patients Seek Bariatric Surgery: Does Insurance Coverage Matter?. Obesity Surgery, 2014, 24, 961-964.	1.1	16

126 Clinical use of sibutramine. Drugs of Today, 2004, 40, 41.

2.4 15

#	Article	IF	CITATIONS
127	Changes in Rat Adipocyte and Liver Glucose Metabolism Following Repeated Restraint Stress. Experimental Biology and Medicine, 2001, 226, 312-319.	1.1	14
128	Socioeconomic Status and Health Disparity in the United States. Journal of Human Behavior in the Social Environment, 2007, 15, 13-23.	1.1	14
129	Development of an Internet/Population-Based Weight Management Program for the U.S. Army. Journal of Diabetes Science and Technology, 2008, 2, 116-126.	1.3	14
130	An Environmental Intervention to Prevent Excess Weight Gain in African-American Students: A Pilot Study. American Journal of Health Promotion, 2010, 24, 340-343.	0.9	14
131	Blood pressure and heart failure risk among diabetic patients. International Journal of Cardiology, 2014, 176, 125-132.	0.8	14
132	Energy expenditure and weight control: Is the biggest loser the best loser?. Obesity, 2016, 24, 1607-1608.	1.5	14
133	Drug Treatment of Obesity. Psychiatric Clinics of North America, 2011, 34, 871-880.	0.7	13
134	Changes in food intake and body weight associated with basic combat training. Military Medicine, 2002, 167, 248-53.	0.4	13
135	Appetitive Operant Behavior and Free-Feeding in Rats Exposed to Acute Stress. Physiology and Behavior, 1997, 62, 827-830.	1.0	12
136	The Effects of Restraint Stress on Intake of Preferred and Nonpreferred Solutions in Rodents. Physiology and Behavior, 1998, 65, 697-704.	1.0	12
137	Neuroautoantibody immunoreactivity in relation to aging and stress in apolipoprotein E-deficient mice. Brain Research Bulletin, 1999, 49, 173-179.	1.4	12
138	Risks and benefits of weight loss: challenges to obesity research. Country Review Ukraine, 2005, 7, L27-L31.	0.8	12
139	What Should I Eat and Why? The Environmental, Genetic, and Behavioral Determinants of Food Choice: Summary from a Pennington Scientific Symposium. Obesity, 2020, 28, 1386-1396.	1.5	12
140	Drugs for Treating Obesity. Handbook of Experimental Pharmacology, 2021, , 387-414.	0.9	12
141	Efficacy of a Pilot Internet-Based Weight Management Program (H.E.A.L.T.H.) and Longitudinal Physical Fitness Data in Army Reserve Soldiers. Journal of Diabetes Science and Technology, 2011, 5, 1255-1262.	1.3	11
142	Consistency of fat mass–fat-free mass relationship across ethnicity and sex groups. British Journal of Nutrition, 2011, 105, 1272-1276.	1.2	10
143	Return on Investment: Medical Savings of an Employer‧ponsored Digital Intensive Lifestyle Intervention for Weight Loss. Obesity, 2021, 29, 654-661.	1.5	10
144	Response to "the need for people-first language in our <i>obesity</i> journal― Obesity, 2015, 23, 918-918.	1.5	9

#	Article	IF	CITATIONS
145	Implementing an Online Weightâ€Management Intervention to an Employee Population: Initial Experience with Real Appeal. Obesity, 2018, 26, 1704-1708.	1.5	9
146	What the new obesity guidelines will tell us. Current Opinion in Endocrinology, Diabetes and Obesity, 2013, 20, 429-433.	1.2	8
147	Baton Rouge Healthy Eating and Lifestyle Program (BR-HELP): A Pilot Health Promotion Program. Journal of Prevention and Intervention in the Community, 2015, 43, 95-108.	0.5	8
148	History of Cardiovascular Disease, Intensive Lifestyle Intervention, and Cardiovascular Outcomes in the Look AHEAD Trial. Obesity, 2020, 28, 247-258.	1.5	8
149	Lorcaserin Departs, Leaving More Questions than Answers. Obesity, 2020, 28, 1167-1167.	1.5	8
150	Semaglutide for obesity: four STEPs forward, but more to come. Lancet Diabetes and Endocrinology,the, 2021, 9, 252-254.	5.5	8
151	BMI Guidelines for Bariatric Surgery in Diabetes: How Low Can We Go?. Diabetes Care, 2012, 35, 1399-1400.	4.3	7
152	The Effects of Triiodothyronine on Bone Metabolism in Healthy Ambulatory Men. Thyroid, 2003, 13, 357-364.	2.4	6
153	Triiodothyronine increases calcium loss in a bed rest antigravity model for space flight. Metabolism: Clinical and Experimental, 2008, 57, 1696-1703.	1.5	6
154	The Global Pandemic of Overweight and Obesity. , 2021, , 739-773.		6
155	People United to Sustain Health (PUSH): A Communityâ€Based Participatory Research Study. Clinical and Translational Science, 2014, 7, 108-114.	1.5	5
156	Predictors for Selection of Insuranceâ€Funded Weight Loss Approaches in Individuals With Severe Obesity. Obesity, 2015, 23, 1151-1158.	1.5	4
157	The Global Pandemic of Overweight and Obesity. , 2020, , 1-35.		4
158	Better nutrient data improves public health: evidence and examples from the Dietary Approaches to Stop Hypertension (DASH) Trial. Journal of Food Composition and Analysis, 2003, 16, 313-321.	1.9	3
159	Medical Management of Obesity in Women: Office-Based Approaches to Weight Management. Clinical Obstetrics and Gynecology, 2004, 47, 914-927.	0.6	3
160	Five-Year Medical and Pharmacy Costs after a Medically Supervised Intensive Treatment Program for Obesity. American Journal of Health Promotion, 2014, 28, 364-371.	0.9	3
161	Weighing up dietary patterns – Authors' reply. Lancet, The, 2016, 388, 759-760.	6.3	3
162	Energy Balance and Weight Loss for Diabetes Remission. Diabetes Spectrum, 2020, 33, 117-124.	0.4	3

#	Article	IF	CITATIONS
163	2020: It Was Quite a Year!. Obesity, 2021, 29, 9-10.	1.5	3
164	Comparison of Weight-Loss Diets With Different Compositions of Fat, Protein, and Carbohydrates. Obstetrical and Gynecological Survey, 2009, 64, 460-462.	0.2	2
165	Phentermine plus topiramate in the treatment of obesity – Authors' reply. Lancet, The, 2011, 378, 126-127.	6.3	2
166	Perceptions Community Residents Have about Partner Institutions and Clinical Research. Clinical and Translational Science, 2013, 6, 469-473.	1.5	2
167	Turning the pages of <i>Obesity</i> . Obesity, 2013, 21, 1-1.	1.5	2
168	State of the journal 2014. Obesity, 2014, 22, 1-1.	1.5	2
169	New medications and new ways to use them. Obesity, 2015, 23, S1-4.	1.5	2
170	We stand by our guidelines. Nature Reviews Endocrinology, 2014, 10, 310-310.	4.3	1
171	Editorial: A timely topic. Obesity, 2015, 23, S1-S1.	1.5	1
172	2014 - It's been quite a year. Obesity, 2015, 23, 1-1.	1.5	1
173	Medical Approaches to Weight-Centric Management of Obese Patients with Type 2 Diabetes. , 2016, , 47-59.		1
174	Keeping the baby and throwing out the bathwater. Obesity, 2017, 25, 659-659.	1.5	1
175	Methodological issues with metaâ€analysis. Diabetes, Obesity and Metabolism, 2022, 24, 1681-1681.	2.2	1
176	Reply to G Taubes, MI Friedman, and V Torres-Carot et al. American Journal of Clinical Nutrition, 2022, 116, 614-615.	2.2	1
177	Weight Loss as the Primary Treatment for Type 2 Diabetes. Obesity Management, 2005, 1, 96-99.	0.2	Ο
178	Report from the CORE at Pennington Biomedical Research Center. Obesity Management, 2006, 2, 190-192.	0.2	0
179	Supplements Used in Weight Management. Obesity Management, 2006, 2, 186-189.	0.2	0
180	Pennington Biomedical Research Center: Do You Practice What You Preach?. Obesity and Weight Management, 2009, 5, 290-291.	0.1	0

#	Article	IF	CITATIONS
181	The Expert Weighs In: Weight Loss in Patients with Diabetes: Lessons from the Look AHEAD Study: An Interview with Rena Wing, PhD. Obesity and Weight Management, 2009, 5, 268-272.	0.1	0
182	Safeway's Approach to Healthcare Cost Cutting. Obesity and Weight Management, 2009, 5, 261-262.	0.1	0
183	We want you back. Obesity, 2014, 22, 1393-1393.	1.5	Ο
184	Introduction to the special online issue: Eat, sleep, exercise. Obesity, 2014, 22, E1.	1.5	0
185	2015, A year in review for readers of Obesity. Obesity, 2016, 24, 9-9.	1.5	Ο
186	George A. Bray, MD: Progress in Obesity—Multidisciplinary Research, Multidimensional Man. Diabetes Care, 2016, 39, 1481-1485.	4.3	0
187	What Will It Take for Mexico to Bend the Curve?. Obesity, 2018, 26, 1525-1526.	1.5	0
188	Medications Indicated for Chronic Weight Management. Endocrinology, 2019, , 401-424.	0.1	0
189	Eating behaviors and strategies to promote weight loss and maintenance. , 2020, , 159-183.		0
190	Stress and Macronutrient Selection. , 1999, , .		0
191	The Doctor's Tool Kit: Pharmacotherapy for the Patient with Obesity. Growth Hormone, 2015, , 91-109.	0.2	0
192	Medications Indicated for Chronic Weight Management. Endocrinology, 2017, , 1-24.	0.1	0